David Shaw’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

David Shaw’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32,782	Closed	-$167K	–	6034
2022 Q1	$167K	Sell	32,782 -117,880	-78%	-$741K	﹤0.01%	4911
2021 Q4	$848K	Sell	150,662 -149,493	-50%	-$1.27M	﹤0.01%	4067
2021 Q3	$3.33M	Sell	300,155 -2,414	-0.8%	-$30.3K	﹤0.01%	2519
2021 Q2	$5.13M	Buy	302,569 +254,518	+530%	+$4.82M	﹤0.01%	2014
2021 Q1	$1.26M	Buy	48,051 +35,084	+271%	+$1.59M	﹤0.01%	2928
2020 Q4	$469K	Buy	+12,967	New	+$469K	﹤0.01%	3420
2020 Q3	–	Sell	-755	Closed	-$32K	–	4299
2020 Q2	$32K	Buy	+755	New	+$50.9K	﹤0.01%	3936

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

David Shaw's EVFM Position: Q2 2022 in Review

David Shaw sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 32,782 shares — an estimated $167K sold.

David Shaw first reported a position in EVFM in Q2 2020 and held it in 7 quarters. The position peaked at $5.13M in Q2 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

David Shaw reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
David Shaw sold 32,782 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $167K.
David Shaw first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
David Shaw's Evofem Biosciences, Inc. Common Stock position peaked at $5.13M in Q2 2021.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.